Laurus Labs Share News - Latest Updates, Live News & More

Latest news about Laurus Labs

Laurus Labs Reports Strong Q2 FY26 Results with 35% Revenue Growth and Margin Expansion Oct 28, 2025

Laurus Labs Limited reported robust Q2 FY26 results with revenue of INR 1,653.00 crores, up 35%. EBITDA margins expanded to 26%. ARV business contributed INR 733.00 crores, while CDMO division recorded INR 471.00 crores in sales. The company received 532 acres from Andhra Pradesh government for a new manufacturing complex and invested in ADC technology. Laurus Labs maintains its ARV sales guidance and plans significant capex investments for future growth.

Laurus Labs Boosts Gross Margin Forecast to 60%, Unveils Major Expansion Plans Amid Mixed Analyst Reactions Oct 24, 2025

Laurus Labs Reports Strong Q2 Performance with 35% Revenue Growth and Significant Margin Expansion Oct 23, 2025

Laurus Labs Approves Q2 FY26 Results, Declares Rs 0.80 Interim Dividend Oct 23, 2025

Laurus Labs Reports Impressive Q2 FY26 Results with 35% Revenue Growth and Doubled EBITDA Oct 23, 2025

More news about Laurus Labs

14Oct 25

Laurus Labs Reports Strong Growth in September Quarter

Laurus Labs, a key player in the pharmaceutical industry, has reported significant growth figures for the September quarter. The company achieved a 65.00% growth in the quarter and a 52.00% growth for the month of September alone. These strong double-digit growth rates across both monthly and quarterly timeframes indicate a positive trend for the company, potentially reflecting increased demand or successful expansion strategies.

26Sept 25

Laurus Labs Shrugs Off US Pharma Tariff Impact, Stock Dips 8.2%

Laurus Labs anticipates limited effects from upcoming US tariffs on branded pharmaceutical products. CEO Satyanarayana Chava explained that the company's diverse revenue streams, including 40% from ARV drugs sold to Africa, 27% from non-ARV generics exempt from tariffs, and 33% from CDMO operations, provide insulation. Only 5% of CDMO sales go to the US, with tariff costs likely passed to clients. Despite an 8.2% stock drop following the news, Laurus Labs' shares have gained 81% over the past year.

16Sept 25

Laurus Labs Reports Impressive 94% Export Growth in August

Laurus Labs, a key player in the pharmaceutical industry, has announced a significant 94.00% growth in its export business for August. This substantial increase indicates a strong expansion of the company's international market presence and could potentially lead to increased revenue and enhanced competitive positioning in the global pharmaceutical landscape.

12Sept 25

Laurus Labs Reports Robust Q1 Performance with 31% Revenue Growth and Expanding CDMO Business

Laurus Labs reported impressive Q1 financial results with revenue of ₹1,570.00 crores, up 31% year-over-year. EBITDA increased to ₹389.00 crores with margins improving to 24.80%. Net profit surged 1,154% to ₹163.00 crores. The CDMO business contributed 28% of total revenues, growing at a 32% CAGR over FY20-25. Gross margins remained healthy at 59.40%. The company is expanding capacity in gene therapy, ADCs, and fermentation, while investing 4.30% of revenues in R&D. Laurus Labs supported over 75 R&D projects in FY25 and saw increases in Bio-catalysis and Continuous Flow Reaction projects.

21Aug 25

Laurus Labs Unveils Strategic Restructuring Plan for 2026

Laurus Labs Limited has unveiled a corporate restructuring plan starting April 1, 2026. The plan involves demerging Laurus Synthesis Private Limited's (LSPL) Unit-1 and merging it with Sriam Labs Private Limited, while the remaining LSPL business will be amalgamated with Laurus Labs. Sriam Labs will issue 27 equity shares for every 1 share held by Laurus Labs in LSPL. The restructuring aims to consolidate similar businesses, enhance financial strength, and simplify the group structure. The plan is subject to regulatory approvals and will not change Laurus Labs' shareholding pattern.

29Jul 25

Laurus Labs Reports Strong Q1 Performance with 31% Revenue Growth, CDMO Business Drives Margins

Laurus Labs Limited reported robust Q1 financial results with total income from operations reaching INR 1,570.00 crores, a 31% year-on-year growth. The CDMO business emerged as a key growth driver, with sales reaching INR 493.00 crores. The company announced three major capacity expansions and plans to invest INR 5,000.00 crores over the next 4-5 years. Management expects the CDMO segment to potentially contribute 50% of revenue in the medium term, up from the current 30%. The company maintains a positive outlook with projected growth in the CDMO segment and stable ARV business performance.

28Jul 25

Laurus Labs Targets 25% EBITDA Margins, Secures 531.77 Acres for Expansion

Laurus Labs projects improved profitability with 55-60% gross margins and 25% EBITDA margin for the current financial year. The company expects CDMO revenue to exceed 30% of total revenue, targeting ₹2,000 crore annually. Laurus Labs has secured 531.77 acres in Andhra Pradesh for the Laurus Pharma Zone, planning a ₹5,630 crore investment and 6,350 new jobs over eight years.

27Jul 25

Laurus Labs Secures 532-Acre Land for ₹5,630 Crore Pharma Zone in Andhra Pradesh

Laurus Labs has been allotted 531.77 acres of land by the Andhra Pradesh government in IP Rambilli Phase-II, Anakapalli District, for establishing the Laurus Pharma Zone (LPZ). The company plans to invest ₹5,630.00 crores over three phases in eight years, creating 6,350 jobs. This expansion aims to enhance Laurus Labs' manufacturing capabilities in the pharmaceutical sector.

25Jul 25

Laurus Labs Reports Strong Q1 Results, Exceeding Estimates Across Key Metrics

Laurus Labs reported impressive Q1 results, exceeding market expectations. Revenue reached ₹15.70 billion, up from ₹11.90 billion year-over-year. Consolidated net profit surged to ₹1.63 billion from ₹125 million. EBITDA doubled to ₹3.82 billion with a margin of 24.35%. The Formulations segment grew over 40%, CDMO segment saw over 100% year-over-year growth, and ARV business is expected to contribute ₹2,500 crore to sales. The company maintains a pipeline of over 110 active CDMO projects.

10Jul 25

Laurus Labs' Exports Soar by 221%, Reaching $106 Million

Laurus Labs, a pharmaceutical company, has announced a significant increase in its exports, reaching $106.00 million as of June 25. This represents a 221% growth compared to a previous period. The substantial rise in exports could indicate expanded market reach, increased product demand, or successful penetration into new international markets. This development is likely to positively impact the company's revenue and competitive position in the global pharmaceutical industry.

16Jun 25

Laurus Labs Doubles Exports in May, Showcasing Remarkable Growth

Laurus Labs, a pharmaceutical company, has experienced a significant increase in its export performance for May. The company's exports have more than doubled, showing a 104.00% increase compared to the same period last year. This surge indicates an expansion of Laurus Labs' global footprint and suggests potential for enhanced revenue from international sales. The growth also implies improved operational efficiency and a strengthened position in the global pharmaceutical market.

26Apr 25

Laurus Labs Reports Strong Q4 FY25, Eyes 24% EBITDA Margin in FY26

Laurus Labs Limited reported robust Q4 FY25 results with 19% revenue growth to Rs 1,720.00 crore and tripled net profit to Rs 234.00 crore. For FY26, the company projects EBITDA margins of 24.00-24.50% and expects better revenue growth than FY25. The CDMO segment is anticipated to match generics contribution in the next five years. Strong demand in CDMO, asset leverage, and operational efficiency are driving the positive outlook.

24Apr 25

Laurus Labs Q4 Profit Surges 210%, Margins Exceed 20% for Second Quarter

Laurus Labs posted a consolidated net profit of ₹233.60 crore in Q4 FY24, up 210% year-over-year. Revenue increased by 18.97% to ₹1,424.50 crore, while EBITDA grew 74% to ₹419 crore. EBITDA margins expanded to 24.5%, marking the second consecutive quarter above 20%. However, annual revenue for FY24 declined 16.20% to ₹5,067.20 crore, with net profit down 78.89% to ₹168.20 crore.

15Apr 25

Laurus Labs Secures USFDA Approval for API Facility in Andhra Pradesh

Laurus Labs Limited has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Atchutapuram, Andhra Pradesh. The inspection, conducted from January 27 to 31, 2025, validates the company's compliance with good manufacturing practices. This approval strengthens Laurus Labs' position in the global pharmaceutical supply chain and potentially opens up new opportunities in the U.S. market.

11Apr 25

Laurus Labs Reports Robust Export Growth; Q4 FY25 Results Anticipated

Laurus Labs, a leading Indian CDMO, reported an 18% YoY increase in total exports to $53 million, with Q4 exports surging 60% YoY. The company will announce its Q4 and FY25 results on April 24, 2025, along with considering a 2nd Interim Dividend. An earnings call is scheduled for the same day at 5:00 PM IST. Laurus Labs, founded in 2005, is a global leader in API manufacturing with 14 manufacturing sites and over 6,700 employees.

07Mar 25

Laurus Labs Invests ₹83.3 Crore in KRKA Pharma JV for New Manufacturing Facility

Laurus Labs Limited has approved an investment of ₹83.3 crore in its joint venture, KRKA Pharma Private Limited. The total investment of ₹170 crore, including ₹86.7 crore from co-venturer KRKA d.d., Novo Mesto, Slovenia, will be used to acquire land for a new manufacturing facility, cover initial setup costs, and produce finished products for new markets, including India. The shareholding ratio will remain at 51:49 (KRKA d.d., Novo Mesto : Laurus Labs). The investment, expected to be completed by March 31, 2025, aligns with Laurus Labs' long-term growth strategy in the pharmaceutical industry.

21Feb 25

Laurus Labs Faces Delay in USAID HIV Funds Release Despite Favorable Court Ruling

Laurus Labs, a major pharmaceutical company, has won a court ruling regarding USAID HIV funds but is unable to access them. This delay could impact the company's HIV drug production and distribution, potentially affecting operational targets and financial performance. The situation introduces uncertainty into Laurus Labs' financial outlook, with potential implications for its market position and investor confidence. No official statement has been released by the company regarding this matter.